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Clinical Guidelines MoonTranscatheter therapies for mitral regurgitation: A surgeon’s
perspectiveMarc R. Moon, MDThe American College of Cardiology, American Associa-
tion for Thoracic Surgery, Society of Thoracic Surgeons
(STS), and Society of Cardiovascular Angiography and
Interventions collaborated to write an overview of
transcatheter therapies for mitral regurgitation (MR),
which has been published in the March 2014 issue of
The Journal of Thoracic and Cardiovascular Surgery.1
The multisocietal document included a summary of the
current results of standard mitral valve (MV) surgery
and a summary of clinical trials of transcatheter MR
therapies and identified critical components for a success-
ful program. The document was developed to address
critical issues for implementation of innovative transcath-
eter MR therapies for selected patients and to help frame
future discussions as the technology continues to evolve
while “maintaining the best interests of the patients” as
the driving force behind the initiative. The present brief
synopsis summarizes the aspects of the multisocietal
document that are of most interest to surgeons.
The results with standard MV surgery for MR have
generally been outstanding for most patients at experienced
centers. Degenerative MR secondary to isolated posterior
leaflet pathologic features can be successfully repaired
in >95% of patients, with a mortality rate of <1% to
2%. Less invasive approaches have become attractive
because of the potential to diminish postoperative discom-
fort and complications and hasten the return to normal ac-
tivities; however, such approaches should not be endorsed
without ensuring a reasonable likelihood of a durable result.
Of the numerous devices currently under investigation, the
edge-to-edge MitraClip device (Abbott Vascular, Santa
Clara, Calif) has undergone the most extensive human
testing in the United States.2-4 The MitraClip was modeled
after the Alfieri double-orifice technique, which has been
used successfully as an adjunct for complex MV repair
and to decrease the risk of systolic anterior motion in
selected cases.5,6
The MitraClip was approved in October 2013 by the
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selected patients determined to be at prohibitive risk of
open surgery by an experienced heart team.1 Approval
was based, to a large degree, on the results from the Endo-
vascular Valve Edge-to-Edge Repair Study (EVEREST) II
trial, which randomized 279 patients with severe MR in a
2:1 ratio to the transcatheter MitraClip (n ¼ 184) or open
surgery (n ¼ 95).4 As expected, the transfusion rates
(45% vs 13%) and incidence of major morbidity (9% vs
2%), as defined by the STS, were greater with open surgery;
however, the mortality rate was similar (1%-2%), and sur-
gery forMV dysfunction was more common after transcath-
eter repair (20% vs 2%). In the original intention-to-treat
analysis, 21 patients who refused treatment after randomi-
zation (6 transcatheter, 15 open surgery) were assumed to
have persistent MR for the primary efficacy analysis
(freedom from death, surgery for MV dysfunction, or 3þ
or 4þMR). Thus, for all 279 patients, the primary efficacy
at 12 months had been reached for 55% of the transcatheter
and 73% of the open surgery patients (P¼ .007). Excluding
those patients who had refused treatment after randomiza-
tion increased the primary efficacy to 57% for the trans-
catheter group and 88% for the open surgery group.
Subgroup analysis demonstrated that the efficacy was better
with open surgery for younger patients (<70 years old),
degenerative MR, and ejection fraction 60%. At 4 years,
survival was similar but late MR was less common after
open surgery (P<.001, Figure 1).7
As with most innovative procedures, the results seemed
to improvewith increased experience8 and patient selection,
specifically high-risk surgical patients.9-12 Whitlow and as-
sociates9 studied transcatheter MitraClip use in 78 patients
with an STS surgical risk of 12%. Mortality at 30 days was
7.7% compared with 8.3% in a comparator group of open
surgery patients who had been screened for, but not enrolled
in, the EVEREST II trial. At 1 year, 24% of the transcath-
eter patients had died. However, among the survivors, 78%
had MR grade 2þ and most had experienced improved
symptoms, quality of life, left ventricular reverse remodel-
ing, and decreased readmissions for heart failure. Several
other studies have corroborated the satisfactory results in
high-risk subsets,10-12 in particular, those with functional
MR,13,14 which is being evaluated in 2 current trials (Clin-
ical Outcomes Assessment of the MitraClip Percutaneous
Therapy for Extremely High-Surgical-Risk Patients
[COAPT] and A Randomized Study of the MitraClip De-
vice in Heart Failure Patients With Clinically Significant
Functional Mitral Regurgitation [RESHAPE-HF]).15,16ery c March 2014
FIGURE 1. Mitral regurgitation grade at 4 years in the Endovascular
Valve Edge-to-Edge Repair Study (EVEREST) II trial for patients random-
ized to transcatheter mitral regurgitation (MR) therapy with the MitraClip
device or open surgery (based on data from Mauri and colleagues7).
Moon Clinical GuidelinesSURGICAL INTERVENTION AFTER FAILED
TRANSCATHETER MR REPAIR
Geidel and Schmoeckel17 reported 19 patients who had
undergone open MV surgery 12 days (median) after failed
transcatheter MitraClip placement. The EuroSCORE had
increased from 13% at MitraClip implantation to 27% at
open surgery. MV repair was possible in 83% of patients
who had had only 1 clip implanted; however, replacement
was necessary in 77% of the patients who had had 2 clips
implanted. Glower and colleagues18 also noted leaflet dam-
age in 30% of patients after failed transcatheter repair, with
fibrosis and leaflet scarring most common after 30 days.
MV replacement was necessary in 17 of 37 patients
(46%) with a failed transcatheter procedure compared
with only 13 of 80 patients (16%) initially randomized to
open surgery.GUIDELINES FOR OPERATOR TRAINING, CARE
PROTOCOLS, AND OUTCOMES ASSESSMENT
The challenges of evaluating and treating patients with
complex cardiac disease and significant comorbidities re-
quires a multidisciplinary team at a high-volume center.
The model established during release of transcatheter aortic
valve replacement, including the heart team paradigm,
should pertain to the dissemination of transcatheter MV
therapies.1,19,20 The clinical cardiologist will most often
determine the timing of referral for intervention and then
works with the interventional cardiologist and cardiac
surgeon to determine the best course of therapy. Imaging
specialists are essential to delineate the anatomic limitations
to the various treatment options and to provide imaging
capabilities during interventions. (The current relative
technical limitations to transcatheter MitraClip implantation
include pathologic findings isolated to the A2-P2 area, aThe Journal of Thoracic and Cacoaptation length of 2 mm, a coaptation depth of 11 mm, a
flail gap<10 mm, a flail width<15 mm, an MV orifice
area>4 cm2, and a mobile leaflet length>1 cm.) The inter-
ventional cardiologist must be skilled in all aspects of trans-
catheter structural procedures, and the cardiac surgeon must
be competent in catheter-based and surgical approaches to
MR, including repair and replacement options. The multiso-
cietal document1 has specified: “The cardiac surgeon and
interventional cardiologist will collaborate during the perfor-
mance of transcatheter mitral procedures and will designate
primary and secondary operator as appropriate for the specific
findings and challenges encountered in any individual pa-
tient,” noting that “Procedural teams function best with both
disciplines represented and working collaboratively.”
Protocols outlining the roles of the individual heart team
members and establishing a collaborative process for shared
decision making with the patient are important. A detailed
outline of the facilities, personnel experience, care proto-
cols, and complication management strategies must be
developed. The preoperative evaluation should include a
complete assessment of the comorbidities, cardiac function,
valvular anatomy and mechanics, and the need for coronary
revascularization. A hybrid operating suite with capability
for cardiopulmonary bypass is not strictly necessary for cur-
rent transcatheter MV therapies but will become necessary
if transcatheter MV replacement options materialize and
could add a level of security if complications occur rapidly
during transcatheter repair. Laminar air flow is mandatory
to provide operating room level sterility. The specific com-
petency requirements for individual and institutional expe-
rience with transcatheter and open surgical procedures and
the specific criteria for training and performance metrics
will be outlined in a forthcoming multisocietal consensus
statement. The addition of transcatheter MR therapies to
the STS/American College of Cardiology Transcatheter
Valve Therapy registry with reporting of postprocedural
30-day and 1-year outcomes will be essential to monitor
the safety and efficacy of these new technologies.21 The
multisocietal document1 concluded with the following
recommendations:
1. Heart valve centers of excellence are defined by the
competence of the individual members and the presence
of a multidisciplinary heart team that works collabora-
tively in the best interest of patients. All aspects of pa-
tient evaluation, care, and follow-up, including
mandatory participation in the Transcatheter Valve Ther-
apy registry, must be addressed with dedicated path-
ways.
2. Availability and reimbursement for new devices should
be limited to heart valve centers of excellence that
meet national criteria.
3. Operator training and credentialing criteria must be es-
tablished by a multisocietal group.rdiovascular Surgery c Volume 147, Number 3 851
Clinical Guidelines Moon4. Guidelines for transcatheter MV interventions should be
substantiated and developed, with performance mea-
sures and appropriate use criteria for expanded indica-
tions based on rigorous trials and registry assessment.
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